These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 29535126)

  • 21. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
    Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas
    Satouchi M; Tanaka H; Yoshioka H; Shimokawaji T; Mizuno K; Takeda K; Yoshino I; Seto T; Kurata T; Tashiro N; Hagiwara K
    Lung Cancer; 2017 Sep; 111():190-194. PubMed ID: 28838392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selecting short length nucleic acids localized in exosomes improves plasma
    Kim Y; Shin S; Kim B; Lee KA
    Cancer Cell Int; 2019; 19():251. PubMed ID: 31582907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.
    Yang K; Li J; Zhao J; Ren P; Wang Z; Wei B; Dong B; Sun R; Wang X; Groen HJM; Ma J; Guo Y
    Anal Chem; 2018 Oct; 90(19):11203-11209. PubMed ID: 30156405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure.
    Zhou J; Zhao C; Zhao J; Wang Q; Chu X; Li J; Zhou F; Ren S; Li X; Su C; Zhou C
    Thorac Cancer; 2019 Apr; 10(4):957-965. PubMed ID: 30887673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.
    Qian X; Liu J; Sun Y; Wang M; Lei H; Luo G; Liu X; Xiong C; Liu D; Liu J; Tang Y
    Oncotarget; 2016 May; 7(20):29154-65. PubMed ID: 27081078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
    Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
    J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
    Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
    Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
    Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discrimination of Germline
    Hu Y; Alden RS; Odegaard JI; Fairclough SR; Chen R; Heng J; Feeney N; Nagy RJ; Shah J; Ulrich B; Gutierrez M; Lanman RB; Garber JE; Paweletz CP; Oxnard GR
    Clin Cancer Res; 2017 Dec; 23(23):7351-7359. PubMed ID: 28947568
    [No Abstract]   [Full Text] [Related]  

  • 33. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring
    Kogure Y; Shigematsu F; Oki M; Saka H
    In Vivo; 2018; 32(5):1199-1204. PubMed ID: 30150444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study.
    Mistry R; Patil A
    Indian J Cancer; 2017 Dec; 54(Supplement):S65-S66. PubMed ID: 29292710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.
    Szpechcinski A; Bryl M; Wojcik P; Czyzewicz G; Wojda E; Rudzinski P; Duk K; Moes-Sosnowska J; Maszkowska-Kopij K; Langfort R; Barinow-Wojewodzki A; Chorostowska-Wynimko J
    Adv Med Sci; 2021 Sep; 66(2):336-342. PubMed ID: 34274564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
    Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
    J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.
    Suzawa K; Yamamoto H; Ohashi K; Hashida S; Tomida S; Kubo T; Maki Y; Soh J; Tsukuda K; Kiura K; Miyoshi S; Toyooka S
    Oncol Rep; 2017 May; 37(5):3100-3106. PubMed ID: 28405680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.
    Wan Y; Liu B; Lei H; Zhang B; Wang Y; Huang H; Chen S; Feng Y; Zhu L; Gu Y; Zhang Q; Ma H; Zheng SY
    Ann Oncol; 2018 Dec; 29(12):2379-2383. PubMed ID: 30339193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
    Reckamp KL; Melnikova VO; Karlovich C; Sequist LV; Camidge DR; Wakelee H; Perol M; Oxnard GR; Kosco K; Croucher P; Samuelsz E; Vibat CR; Guerrero S; Geis J; Berz D; Mann E; Matheny S; Rolfe L; Raponi M; Erlander MG; Gadgeel S
    J Thorac Oncol; 2016 Oct; 11(10):1690-700. PubMed ID: 27468937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.